|
1
|
Bergstrom G, Persson M, Adiels M, Björnson
E, Bonander C, Ahlström H, Alfredsson J, Angerås O, Berglund G,
Blomberg A, et al: Prevalence of subclinical coronary artery
atherosclerosis in the general population. Circulation.
144:916–929. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Morcos SK, Thomsen HS and Webb JA:
Contrast Media Safety Committee of the European Society of
Urogenital Radiology. Prevention of generalized reactions to
contrast media: A consensus report and guidelines. Eur Radiol.
11:1720–1728. 2001.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Davenport MS, Perazella MA, Yee J, Dillman
JR, Fine D, McDonald RJ, Rodby RA, Wang CL and Weinreb JC: Use of
intravenous iodinated contrast media in patients with kidney
disease: consensus statements from the american college of
radiology and the national kidney foundation. Kidney Med. 2:85–93.
2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Arnett DK, Blumenthal RS, Albert MA,
Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A,
Lloyd-Jones D, McEvoy JW, et al: 2019 ACC/AHA guideline on the
primary prevention of cardiovascular disease: A Report of the
American College of Cardiology/American Heart association task
force on clinical practice guidelines. Circulation. 140:e596–e646.
2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Petretta M, Fiumara G, Petretta MP and
Cuocolo A: Detection of silent myocardial ischemia: Is it
clinically relevant? J Nucl Cardiol. 20:707–710. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Proposed standard nomenclature for new
tumor necrosis factor members involved in the regulation of bone
resorption. The American Society for Bone and Mineral Research
President's Committee on Nomenclature. Bone. 27:761–764.
2000.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Boyce BF and Xing L: Biology of RANK,
RANKL, and osteoprotegerin. Arthritis Res Ther. 9 (Suppl
1)(S1)2007.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Hofbauer LC and Heufelder AE: Role of
receptor activator of nuclear factor-kappaB ligand and
osteoprotegerin in bone cell biology. J Mol Med (Berl). 79:243–253.
2001.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Theoleyre S, Wittrant Y, Tat SK, Fortun Y,
Redini F and Heymann D: The molecular triad OPG/RANK/RANKL:
Involvement in the orchestration of pathophysiological bone
remodeling. Cytokine Growth Factor Rev. 15:457–475. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ikebuchi Y, Aoki S, Honma M, Hayashi M,
Sugamori Y, Khan M, Kariya Y, Kato G, Tabata Y, Penninger JM, et
al: Coupling of bone resorption and formation by RANKL reverse
signalling. Nature. 561:195–200. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Simonet WS, Lacey DL, Dunstan CR, Kelley
M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, et
al: Osteoprotegerin: A novel secreted protein involved in the
regulation of bone density. Cell. 89:309–19. 1997.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bucay N, Sarosi I, Dunstan CR, Morony S,
Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, et al:
osteoprotegerin-deficient mice develop early onset osteoporosis and
arterial calcification. Genes Dev. 12:1260–1268. 1998.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Van Campenhout A and Golledge J:
Osteoprotegerin, vascular calcification and atherosclerosis.
Atherosclerosis. 204:321–329. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ma T, Zhao J, Yan Y, Liu J, Zang J, Zhang
Y, Ruan K, Xu H and He W: Plasma osteoprotegerin predicts adverse
cardiovascular events in stable coronary artery disease: The PEACE
trial. Front Cardiovasc Med. 10(1178153)2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Nybo M and Rasmussen LM: The capability of
plasma osteoprotegerin as a predictor of cardiovascular disease: A
systematic literature review. Eur J Endocrinol. 159:603–608.
2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Jono S, Ikari Y, Shioi A, Mori K, Miki T,
Hara K and Nishizawa Y: Serum osteoprotegerin levels are associated
with the presence and severity of coronary artery disease.
Circulation. 106:1192–1194. 2002.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hofbauer LC and Schoppet M: Clinical
implications of the osteoprotegerin/RANKL/RANK system for bone and
vascular diseases. JAMA. 292:490–495. 2004.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Collin-Osdoby P: Regulation of vascular
calcification by osteoclast regulatory factors RANKL and
osteoprotegerin. Circ Res. 95:1046–1057. 2004.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kambayashi Y, Fujimura T, Furudate S, Lyu
C, Hidaka T, Kakizaki A, Sato Y, Tanita K and Aiba S: The
expression of matrix metalloproteinases in receptor activator of
nuclear factor Kappa-B Ligand (RANKL)-expressing Cancer of Apocrine
Origin. Anticancer Res. 38:113–120. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Qian Y and Huang HZ: The role of RANKL and
MMP-9 in the bone resorption caused by ameloblastoma. J Oral Pathol
Med. 39:592–598. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ohshiba T, Miyaura C, Inada M and Ito A:
Role of RANKL-induced osteoclast formation and MMP-dependent matrix
degradation in bone destruction by breast cancer metastasis. Br J
Cancer. 88:1318–1326. 2003.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Heusch G, Libby P, Gersh B, Yellon D, Böhm
M, Lopaschuk G and Opie L: Cardiovascular remodelling in coronary
artery disease and heart failure. Lancet. 383:1933–1943.
2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lieb W, Gona P, Larson MG, Massaro JM,
Lipinska I, Keaney JF Jr, Rong J, Corey D, Hoffmann U, Fox CS, et
al: Biomarkers of the osteoprotegerin pathway: Clinical correlates,
subclinical disease, incident cardiovascular disease, and
mortality. Arterioscler Thromb Vasc Biol. 30:1849–1854.
2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Raaz-Schrauder D, Schrauder MG, Stumpf C,
Lewczuk P, Kilian T, Dietel B, Garlichs CD, Schlundt C, Achenbach S
and Klinghammer L: Plasma levels of sRANKL and OPG are associated
with atherogenic cytokines in patients with intermediate
cardiovascular risk. Heart Vessels. 32:1304–1313. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kiechl S, Schett G, Schwaiger J, Seppi K,
Eder P, Egger G, Santer P, Mayr A, Xu Q and Willeit J: Soluble
receptor activator of nuclear factor-kappa B ligand and risk for
cardiovascular disease. Circulation. 116:385–391. 2007.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhao F, Zhang R, Zhao H, Liu T, Ren M,
Song Y, Liu S and Cong H: Relationship between serum levels of
osteoproteins, inflammatory cytokines and coronary heart disease
and disease severity. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue.
31:588–593. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
27
|
Quercioli A, Montecucco F, Bertolotto M,
Ottonello L, Pende A, Mach F and Dallegri F: Coronary artery
calcification and cardiovascular risk: The role of RANKL/OPG
signalling. Eur J Clin Invest. 40:645–654. 2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Mohammadpour AH, Shamsara J, Nazemi S,
Ghadirzadeh S, Shahsavand S and Ramezani M: Evaluation of RANKL/OPG
serum concentration ratio as a new biomarker for coronary artery
calcification: A pilot study. Thrombosis.
2012(306263)2012.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yu X, Cao L and Yu X: Elevated cord serum
manganese level is associated with a neonatal high ponderal index.
Environ Res. 121:79–83. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Fihn SD, Gardin JM, Abrams J, Berra K,
Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC,
Hinderliter AL, et al: 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS
guideline for the diagnosis and management of patients with stable
ischemic heart disease: Executive summary: A report of the American
College of Cardiology Foundation/American Heart Association task
force on practice guidelines, and the American College of
Physicians, American Association for Thoracic Surgery, Preventive
Cardiovascular Nurses Association, Society for Cardiovascular
Angiography and Interventions, and Society of Thoracic Surgeons.
Circulation. 126:3097–3137. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Xiaoying Li. Geriatric Medicine (a
standardized training textbook for specialists). Beijing: People's
Medical Publishing House, 2015.
|
|
32
|
Lin L, Chen CZ and Yu XD: Analysis of
threshold effects using empower stats software. Zhonghua Liu Xing
Bing Xue Za Zhi. 34:1139–1141. 2013.PubMed/NCBI(In Chinese).
|
|
33
|
Liu Y, Kong X, Wang W, Fan F, Zhang Y,
Zhao M, Wang Y, Wang Y, Wang Y, Qin X, et al: Association of
peripheral differential leukocyte counts with dyslipidemia risk in
Chinese patients with hypertension: Insight from the China stroke
primary prevention trial. J Lipid Res. 58:256–266. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wu J, Geng J, Liu L, Teng W, Liu L and
Chen L: The relationship between estimated glomerular filtration
rate and diabetic retinopathy. J Ophthalmol.
2015(326209)2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yu XD, Zhang J, Yan CH and Shen XM:
Prenatal exposure to manganese at environment relevant level and
neonatal neurobehavioral development. Environ Res. 133:232–238.
2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hou X, Wang C, Wang S, Yang W, Ma Z, Wang
Y, Li C, Li M, Zhang X, Zhao X, et al: Fluctuation between fasting
and 2-H postload glucose state is associated with glomerular
hyperfiltration in newly diagnosed diabetes patients with HbA1c
<7%. PLoS One. 9(e111173)2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Morony S, Tintut Y, Zhang Z, Cattley RC,
Van G, Dwyer D, Stolina M, Kostenuik PJ and Demer LL:
Osteoprotegerin inhibits vascular calcification without affecting
atherosclerosis in ldlr(-/-) mice. Circulation. 117:411–420.
2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Oikonomou E, Siasos G, Tsigkou V, Bletsa
E, Panoilia ME, Oikonomou IN, Sinanidis I, Spinou M, Papastavrou A,
Kokosias G, et al: Coronary artery disease and endothelial
dysfunction: Novel diagnostic and therapeutic approaches. Curr Med
Chem. 27:1052–1080. 2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Sandberg WJ, Yndestad A, Oie E, Smith C,
Ueland T, Ovchinnikova O, Robertson AK, Müller F, Semb AG, Scholz
H, et al: Enhanced T-cell expression of RANK ligand in acute
coronary syndrome: Possible role in plaque destabilization.
Arterioscler Thromb Vasc Biol. 26:857–863. 2006.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Panizo S, Cardus A, Encinas M, Parisi E,
Valcheva P, López-Ongil S, Coll B, Fernandez E and Valdivielso JM:
RANKL increases vascular smooth muscle cell calcification through a
RANK-BMP4-dependent pathway. Circ Res. 104:1041–1048.
2009.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Venuraju SM, Yerramasu A, Corder R and
Lahiri A: Osteoprotegerin as a predictor of coronary artery disease
and cardiovascular mortality and morbidity. J Am Coll Cardiol.
55:2049–2061. 2010.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Kiechl S, Schett G, Wenning G, Redlich K,
Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W and Willeit J:
Osteoprotegerin is a risk factor for progressive atherosclerosis
and cardiovascular disease. Circulation. 109:2175–2180.
2004.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Saely CH, Aczel S, Koch L, Schmid F, Marte
T, Huber K and Drexel H: Diabetes as a coronary artery disease risk
equivalent: Before a change of paradigm? Eur J Cardiovasc Prev
Rehabil. 17:94–99. 2010.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Jung CH and Mok JO: Recent updates on
vascular complications in patients with type 2 diabetes mellitus.
Endocrinol Metab (Seoul). 35:260–271. 2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Collins GS, Reitsma JB, Altman DG and
Moons KG: Transparent reporting of a multivariable prediction model
for individual prognosis or diagnosis (TRIPOD): The TRIPOD
statement. BMJ. 350(g7594)2015.PubMed/NCBI View Article : Google Scholar
|
